Check Cap (NASDAQ:CHEK) posted its earnings results on Friday. The medical research company reported ($0.70) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.82) by $0.12, Fidelity Earnings reports.
NASDAQ CHEK opened at $3.22 on Friday. Check Cap has a 12-month low of $3.08 and a 12-month high of $24.00.
CHEK has been the subject of a number of analyst reports. HC Wainwright set a $14.00 target price on shares of Check Cap and gave the company a “buy” rating in a research report on Wednesday, June 6th. Zacks Investment Research raised shares of Check Cap from a “hold” rating to a “buy” rating and set a $5.00 target price for the company in a research report on Wednesday, May 9th.
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface.
Further Reading: Growth Stocks
Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with MarketBeat.com's FREE daily email newsletter.